Join Cinclus Pharma for a virtual key opinion leader (KOL) event featuring Professor Prateek Sharma, MD, MASGE, FACP, FACG, who will join company management to discuss the unmet need and current treatment landscape for GERD.

The event will include an overview of linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) currently in Phase 3. Linaprazan glurate has a novel mechanism of action, improved pharmacokinetic profile, and the potential for superior efficacy in GERD. It is a prodrug of linaprazan, initially developed and tested by AstraZeneca and has demonstrated stronger gastric acid control than currently available therapies in clinical studies.

The event will cover the burden of GERD, limitations of current treatments, how the mechanism of action of linaprazan glurate may address these gaps and case discussions from real-world GERD patients.

A live question and answer session will follow the formal presentations.